News
Danish drugmakers jump as Eli Lilly's weight-loss pill data disappoints
Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-leading obesity treatment.
Shares of the iPhone maker rose nearly 3%, building on the previous session's rally. Apple announced an extra $100 billion ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...
Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...
Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...
Eli Lilly is eligible for 100M in tax credits to expand its Pleasant Prairie facility, adding 750 jobs and boosting Wisconsin ...
Eli Lilly and Company (NYSE: LLY) is one of the stocks in Jim Cramer’s game plan for this week. Cramer highlighted that his ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback